Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 732 rollover study in thyroid eye disease non-responders or relapsed participants
2025-523280-38-00Phase 2Authorised
- Sponsor
- Amgen
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of AMG 732 in Graves Orbitopathy (GO), sponsored by Amgen. Primary endpoint: Proptosis response status in the study eye. Planned start Jun 2026; status: authorised.
02
Drugs
AMG 732
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2025-523280-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523280-38-00.